Patient preferences, adherence, real-world dosing, and other factors can affect the efficacy of treatment in usual clinical care and potentially limit the generalizability of clinical trial results to ...
NEW YORK CITY -- Patients with borderline personality disorder showed significant improvements when treated with long-acting antipsychotic agent quetiapine fumarate (Seroquel XR) in a ...
December 7, 2009 — The US Food and Drug Administration (FDA) has approved a new indication for quetiapine fumarate extended-release tablets (Seroquel XR, AstraZeneca Pharmaceuticals, LP), allowing ...
In June 2005 and December 2006, Medline, the Cochrane Database of Systematic Reviews, ACP Journal Club, Database of Reviews of Effectiveness, Cochrane Controlled Trials Registry, and International ...
SEROQUEL XR is Now Approved to Treat the Depressive, Manic, and Mixed Episodes of Bipolar Disorder WILMINGTON, Del., Feb. 23 /PRNewswire-FirstCall/ -- AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback